Method of treating asthma or reducing inflammatory cell lung inflammation by administering toll-like receptor 3 antibodies

Patent metadata

Field	Value
Publication number	US-9238693-B2
Application number	US-201313798494-A
Country	US
Kind code	B2
Filing date	Mar 13, 2013
Priority date	Oct 31, 2008
Publication date	Jan 19, 2016
Grant date	Jan 19, 2016

Abstract

Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

First claim

The invention claimed is:

1. A method of treating asthma or asthma exacerbation comprising administering a therapeutically effective amount of an isolated monoclonal antibody or fragment thereof that binds human toll-like receptor 3 (TLR3) to a patient in need thereof for a time sufficient to treat asthma or asthma exacerbation, wherein the isolated antibody
a. comprises a heavy chain complementarity determining region (CDR) 1 (HCDR1), 2 (HCDR2) and 3 (HCDR3) having the amino acid sequences as shown in SEQ ID NOs: 82, 86 and 84, respectively, and a light chain CDR 1 (LCDR1), 2 (LCDR2) and 3 (LCDR3) having the amino acid sequences as shown in SEQ ID NOs: 79, 80 and 87, respectively;
b. comprises the VH of SEQ ID NO: 216 and the VL of SEQ ID NO: 41;
c. comprises a HCDR1, HCDR2 and HCDR3 having the amino acid sequences as shown in SEQ ID NOs: 70, 77 and 72, respectively, and a LCDR1, LCDR2 and LCDR3 having the amino acid sequences as shown in SEQ ID NOs: 67, 68 and 78, respectively; or
d. comprises the VH of SEQ ID NO: 214 and the VL of SEQ ID NO: 211.

2. The method of claim 1 , wherein asthma or asthma exacerbation is associated with an infiltration of inflammatory cells in lung, airway hyperresponsiveness, mucus hypersecretion, subepithelial fibrosis or elevated IgE levels.

3. The method of claim 2 , wherein the inflammatory cells are eosinophils or neutrophils.

4. The method of claim 1 , wherein the isolated monoclonal antibody or fragment thereof that binds TLR3 is human or human-adapted.

5. A method of reducing an infiltration of inflammatory cells in lung comprising administering a therapeutically effective amount of an isolated monoclonal antibody or fragment thereof that binds human toll-like receptor 3 (TLR3) to a patient suffering from a disease associated with increased infiltration of inflammatory cells in lung for a time sufficient to reduce the infiltration of inflammatory cells in lung, wherein the isolated antibody
a. comprises a heavy chain complementarity determining region (CDR) 1 (HCDR1), 2 (HCDR2) and 3 (HCDR3) having the amino acid sequences as shown in SEQ ID NOs: 82, 86 and 84, respectively, and a light chain CDR 1 (LCDR1), 2 (LCDR2) and 3 (LCDR3) having the amino acid sequences as shown in SEQ ID NOs: 79, 80 and 87, respectively;
b. comprises the VH of SEQ ID NO: 216 and the VL of SEQ ID NO: 41;
c. comprises a HCDR1, HCDR2 and HCDR3 having the amino acid sequences as shown in SEQ ID NOs: 70, 77 and 72, respectively, and a LCDR1, LCDR2 and LCDR3 having the amino acid sequences as shown in SEQ ID NOs: 67, 68 and 78, respectively; or
d. comprises the VH of SEQ ID NO: 214 and the VL of SEQ ID NO: 211.

6. The method of claim 5 , wherein the inflammatory cells are neutrophils or eosinophils.

7. The method of claim 5 , wherein the disease associated with increased infiltration of inflammatory cells in lung is asthma, asthma exacerbation, viral infection, influenza virus infection, chronic obstructive pulmonary disease (COPD), allergy, bacterial pneumonia or cystic fibrosis.

8. A method of reducing airway hyperresponsiveness comprising administering a therapeutically effective amount of an isolated monoclonal antibody or fragment thereof that binds human toll-like receptor 3 (TLR3) to a patient suffering from a disease associated with airway hyperresponsiveness for a time sufficient to reduce airway hyperresponsiveness, wherein the isolated antibody
a. comprises a heavy chain complementarity determining region (CDR) 1 (HCDR1), 2 (HCDR2) and 3 (HCDR3) having the amino acid sequences as shown in SEQ ID NOs: 82, 86 and 84, respectively, and a light chain CDR 1 (LCDR1), 2 (LCDR2) and 3 (LCDR3) having the amino acid sequences as shown in SEQ ID NOs: 79, 80 and 87, respectively;
b. comprises the VH of SEQ ID NO: 216 and the VL of SEQ ID NO: 41;
c. comprises a HCDR1, HCDR2 and HCDR3 having the amino acid sequences as shown in SEQ ID NOs: 70, 77 and 72, respectively, and a LCDR1, LCDR2 and LCDR3 having the amino acid sequences as shown in SEQ ID NOs: 67, 68 and 78, respectively; or
d. comprises the VH of SEQ ID NO: 214 and the VL of SEQ ID NO: 211.

9. The method of claim 8 , wherein airway hyperresponsiveness is associated with asthma, asthma exacerbation, viral infection, influenza virus infection, chronic obstructive pulmonary disease (COPD), allergy, allergic rhinitis or cystic fibrosis.

Assignees

• Cunningham Mark
• Feng Yiqing
• Heeringa Katharine
• Luo Jinquan
• Rauchenberger Robert
• Rutz Mark
• San Mateo Lani
• Sarisky Robert
• Sweet Raymond
• Teng Fang
• Teplyakov Alexey
• Wu Sheng-Jiun
• Janssen Biotech Inc

Inventors

• Cunningham Mark
• Feng Yiqing
• Heeringa Katharine
• Luo Jinquan
• Rauchenberger Robert
• Rutz Mark
• San Mateo Lani
• Sarisky Robert
• Sweet Raymond
• Teng Fang
• Teplyakov Alexey
• Wu Sheng-Jiun

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title